embecta has better rebound potential

These two firms have struggled since being spun off by larger medical firms. While both are taking steps to improve their product lineups, we feel embecta is in a better position to rebound from its recent drop.
VIATRIS INC. $12 is a hold. The company (New York symbol… Read More

Cancer drugs should spur Pfizer

PFIZER INC. $28 is a buy. The drugmaker (New York symbol PFE; Income-Growth Dividend Payer Portfolio, Manufacturing sector; Shares outstanding: 5.6 billion; Market cap: $156.8 billion; Dividend yield: 6.0%; Dividend Sustainability Rating: Highest; www.pfizer.com) raised your annual dividend rate by 2.4% with the March 2024 payment, to $0.42 a.. Read More

Our best Wall Street picks for 2024

Here are our top U.S. stock picks for 2024—one each from our Conservative, Aggressive and Income portfolios.
All three are in a strong position to fuel your returns, not only in 2024 but–more importantly–for many years to come. Moreover, their position as market leaders will help… Read More

Pfizer shifts to post-pandemic growth

Pfizer’s shares are down 45% in the past year due to lower demand for its COVID-19 treatments as the pandemic eases. However, new products from its acquisition of Seagen and its high research spending, generally, should spur long-term growth and your dividends.
PFIZER INC. $28 is… Read More